Clinical Policy: Ofatumumab (Arzerra, Kesimpta)
Reference Number: CP.PHAR.306
Effective Date: 02.01.17
Last Review Date: 02.21
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Ofatumumab (Arzerra®, Kesimpta®) is a CD20-directed cytolytic monoclonal antibody.

FDA Approved Indication(s)
Arzerra is indicated:
• In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate
• In combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL
• For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL
• For the treatment of patients with CLL refractory to fludarabine and alemtuzumab

Kesimpta is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Arzerra and Kesimpta are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (must meet all):
      1. Diagnosis of CLL or small lymphocytic lymphoma (SLL);
      2. Request is for Arzerra;
      3. Prescribed by or in consultation with an oncologist or hematologist;
      4. Age ≥ 18 years;
      5. Request meets one of the following (a or b):*
         a. Dose does not exceed the maximum indicated in section V;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   *Prescribed regimen must be FDA-approved or recommended by NCCN.
Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma (off-label) (must meet all):
1. Diagnosis of Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL);
2. Request is for Arzerra;
3. Prescribed by or in consultation with an oncologist or hematologist;
4. Age ≥ 18 years;
5. Member is rituximab-intolerant;
6. Request is for second-line or subsequent therapy (see Appendix B for examples of prior therapy);
7. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*

*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

C. B-Cell Lymphomas (off-label) (must meet all):
1. Diagnosis of one of the following B-cell lymphoma subtypes (a-j):
   a. Follicular lymphoma;
   b. Marginal zone lymphoma (i, ii, iii, or iv):
      i. Splenic marginal zone lymphoma;
      ii. Gastric MALT lymphoma;
      iii. Nongastric MALT lymphoma;
      iv. Nodal marginal zone lymphoma;
   c. Histologic transformation of marginal zone lymphoma to diffuse large B-cell lymphoma;
   d. Diffuse large B-cell lymphoma;
   e. High-grade B-cell lymphoma;
   f. Mantle cell lymphoma;
   g. Castleman’s disease;
   h. Post-transplant lymphoproliferative disorder;
      i. AIDS-related B-cell lymphoma;
      j. Burkitt lymphoma;
2. Request is for Arzerra;
3. Used as a substitute* for rituximab or Gazyva® (obinutuzumab) in patients experiencing rare complications such as mucocutaneous reactions including paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis;

*Caution per NCCN Compendium, re-challenge with the same anti-CD20 monoclonal antibody is not recommended and it is unclear if the use of an alternative anti-CD20 monoclonal antibody poses the same risk of recurrence.
4. Prescribed by or in consultation with an oncologist or hematologist;
5. Age ≥ 18 years;
6. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

D. Multiple Sclerosis (must meet all):*
*The criteria below do not apply to Arizona Complete Health Medicaid (AzCH-CCP) line of business. Please refer to AZ.CP.PHAR.1020 for multiple sclerosis requests for AzCH-CCP members.
1. Diagnosis of one of the following (a, b, or c):
   a. Clinically isolated syndrome, and member is contraindicated to both, or has experienced clinically significant adverse effects to one, of the following at up to maximally indicated doses: an interferon-beta agent (Avonex®, Betaseron®, Rebif®, or Plegridy®), glatiramer (Copaxone®, Glatopa®);
   b. Relapsing-remitting MS, and failure of all of the following at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated (i, ii, iii, and iv):*
      i. Dimethyl fumarate (generic Tecfidera®);
      ii. Aubagio®;
      iii. Gilenya®;
      iv. An interferon-beta agent (Avonex, Betaseron, Rebif, or Plegridy) or glatiramer (Copaxone, Glatopa);
   *Prior authorization is required for all disease modifying therapies for MS
   c. Secondary progressive MS;
2. Request is for Kesimpta;
3. Prescribed by or in consultation with a neurologist;
4. Age ≥ 18 years;
5. Kesimpta is not prescribed concurrently with other disease modifying therapies for MS (see Appendix D);
6. Documentation of baseline number of relapses per year and expanded disability status scale (EDSS) score;
7. At the time of request, member does not have active hepatitis B infection (positive results for hepatitis B surface antigen and anti-hepatitis B virus tests);
8. Dose does not exceed the following:
   a. Initial dose: 20 mg, followed by 20 mg doses 1 and 2 weeks later;
   b. Maintenance dose: 20 mg every 4 weeks.

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

E. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is
II. Continued Therapy

A. All Indications in Section I Other Than Multiple Sclerosis (must meet all):
   1. Currently receiving Arzerra via Centene benefit, or documentation supports that member is currently receiving Arzerra for a covered indication and has received this medication for at least 30 days;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, request meets one of the following (a or b):*
      a. New dose does not exceed the maximum indicated in section V;
      b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration:
Medicaid/HIM – 12 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Multiple Sclerosis (must meet all):*
   *The criteria below do not apply to Arizona Complete Health Medicaid (AzCH-CCP) line of business. Please refer to AZ.CP.PHAR.1020 for multiple sclerosis requests for AzCH-CCP members.
   1. Currently receiving Kesimpta via Centene benefit or member has previously met initial approval criteria;
   2. Member meets one of the following (a or b):
      a. If member has received < 1 year of total treatment: Member is responding positively to therapy;
      b. If member has received ≥ 1 year of total treatment: Member meets one of the following (i, ii, iii, or iv):
         i. Member has not had an increase in the number of relapses per year compared to baseline;
         ii. Member has not had ≥ 2 new MRI-detected lesions;
         iii. Member has not had an increase in EDSS score from baseline;
         iv. Medical justification supports that member is responding positively to therapy;
   3. Kesimpta is not prescribed concurrently with other disease modifying therapies for MS (see Appendix D);
   4. If request is for a dose increase, new dose does not exceed 20 mg every 4 weeks.

Approval duration:
Medicaid/HIM – first re-authorization: 6 months; second and subsequent re-authorizations: 12 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

C. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents;

B. Primary progressive MS.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
CLL: chronic lymphocytic leukemia
EDSS: Expanded Disability Status Scale
FDA: Food and Drug Administration
MS: multiple sclerosis
NCCN: National Comprehensive Cancer Network
SLL: small lymphocytic lymphoma
WM/LPL: Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>WM/LPL primary therapy examples:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• bendamustine/rituximab</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>• bortezomib (Velcade®)/dexamethasone/rituximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Imbruvica® (ibrutinib) ± rituximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• rituximab/cyclophosphamide/dexamethasone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MS therapies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aubagio (teriflunomide)</td>
<td>7 mg or 14 mg PO QD</td>
<td>14 mg/day</td>
</tr>
<tr>
<td>Avonex, Rebif (interferon beta-1a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avonex: 30 mcg IM Q week</td>
<td>Avonex: 30 mcg/week</td>
<td></td>
</tr>
<tr>
<td>Rebif: 22 mcg or 44 mcg SC TIW</td>
<td>Rebif: 44 mcg TIW</td>
<td></td>
</tr>
<tr>
<td>Plegridy (peginterferon beta-1a)</td>
<td>125 mcg SC Q2 weeks</td>
<td>125 mcg/2 weeks</td>
</tr>
<tr>
<td>Betaseron (interferon beta-1b)</td>
<td>250 mcg SC QOD</td>
<td>250 mg QOD</td>
</tr>
<tr>
<td>glatiramer acetate (Copaxone, Glatopa)</td>
<td>20 mg SC QD or 40 mg SC TIW</td>
<td>20 mg/day or 40 mg TIW</td>
</tr>
<tr>
<td>Gilenyia (fingolimod)</td>
<td>0.5 mg PO QD</td>
<td>0.5 mg/day</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/Maximum Dose</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Tecfidera (dimethyl fumarate)</td>
<td>120 mg PO BID for 7 days, followed by 240 mg PO BID</td>
<td>480 mg/day</td>
</tr>
<tr>
<td>Mayzent (siponimod)</td>
<td><strong>All patients:</strong>&lt;br&gt;Day 1 and 2: 0.25 mg PO QD&lt;br&gt;Day 3: 0.5 mg PO QD&lt;br&gt;Day 4: 0.75 mg PO QD&lt;br&gt;CYP2C9 genotypes *1/*1, *1/*2, or *2/*2:&lt;br&gt;Day 5: 1.25 mg PO QD&lt;br&gt;Day 6 and onward: 2 mg PO QD&lt;br&gt;CYP2C9 genotypes *1/*3 or *2/*3:&lt;br&gt;Day 5 and onward: 1 mg PO QD</td>
<td>2 mg/day</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

**Appendix C: Contraindications/Boxed Warnings**
- **Contraindication(s):**
  - Arzerra: none reported
  - Kesimpta: active hepatitis B virus infection
- **Boxed warning(s):**
  - Arzerra: hepatitis B virus reactivation, progressive multifocal leukoencephalopathy
  - Kesimpta: none reported

**Appendix D: General Information**
- Disease-modifying therapies for MS are: glatiramer acetate (Copaxone, Glatopa), interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia®), peginterferon beta-1a (Plegridy), dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity™), monomethyl fumarate (Bafiertam™), fingolimod (Gilenya), teriflunomide (Aubagio), alemtuzumab (Lemtrada®), mitoxantrone (Novantrone®), natalizumab (Tysabri®), ocrelizumab (Ocrevus®), cladribine (Mavenclad®), siponimod (Mayzent), and ozanimod (Zeposia®).
- Of the disease-modifying therapies for MS that are FDA-labeled for clinically isolated syndrome, only the interferon products, glatiramer, and Aubagio have demonstrated any efficacy in decreasing the risk of conversion to MS compared to placebo. This is supported by the AAN 2018 MS guidelines.
V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ofatumumab (Arzerra)</td>
<td>Previously untreated CLL</td>
<td>In combination with chlorambucil: 300 mg IV on Day 1 followed by 1,000 mg IV on Day 8 (Cycle 1). Then 1,000 mg IV on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles</td>
<td>12 cycles</td>
</tr>
<tr>
<td></td>
<td>Relapsed CLL</td>
<td>In combination with fludarabine and cyclophosphamide: 300 mg IV on Day 1 followed by 1,000 mg IV on Day 8 (Cycle 1). Then 1,000 mg IV on Day 1 of subsequent 28-day cycles for a maximum of 6 cycles</td>
<td>6 cycles</td>
</tr>
<tr>
<td></td>
<td>Extended treatment in CLL</td>
<td>300 mg on Day 1 followed by 1,000 mg 1 week later on Day 8, followed by 1,000 mg 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years</td>
<td>2 years</td>
</tr>
<tr>
<td></td>
<td>Refractory CLL</td>
<td>300 mg initial dose, followed 1 week later by 2,000 mg weekly for 7 doses, followed 4 weeks later by 2,000 mg every 4 weeks for 4 doses</td>
<td>12 doses</td>
</tr>
<tr>
<td>Ofatumumab (Kesimpta)</td>
<td>MS</td>
<td>20 mg SC at weeks 0, 1, and 2, followed by 20 mg SC monthly starting at week 4</td>
<td>20 mg</td>
</tr>
</tbody>
</table>

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ofatumumab (Arzerra)</td>
<td>Single-use vial: 100 mg/5 mL, 1,000 mg/50 mL</td>
</tr>
<tr>
<td>Ofatumumab (Kesimpta)</td>
<td>Single-dose prefilled Sensoready pens and prefilled syringes: 20 mg/0.4 mL</td>
</tr>
</tbody>
</table>

VII. References


**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9302</td>
<td>Injection, ofatumumab, 10 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.182.Excellus Oncology.</td>
<td>01.17</td>
<td>02.17</td>
</tr>
<tr>
<td>Policy converted to new template. Annual Review. Safety criteria was applied according to the safety guidance discussed at CPAC and endorsed by Centene Medical Affairs. Added criteria for NCCN 2A rating and above recommended off-label use: Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma. Authorization limits extended from 3 and 6 months to 6 and 12 months for initial and continued approval, respectively.</td>
<td>08.30.17</td>
<td>11.17</td>
</tr>
<tr>
<td>4Q 2018 annual review: no significant changes; HIM added; summarized NCCN and FDA-approved uses for improved clarity; added age requirement and specialist involvement in care; updated continued therapy section to include language for continuity of care; references reviewed and updated.</td>
<td>07.11.18</td>
<td>11.18</td>
</tr>
<tr>
<td>4Q 2019 annual review: NCCN recommendations for B-cell lymphomas added; FDA/NCCN dosing limitation added; 12 doses added as maximum per PI for refractory CLL; Arzerra use in WM/LPL restated as second-line or subsequent therapy; references reviewed and updated.</td>
<td>08.27.19</td>
<td>11.19</td>
</tr>
<tr>
<td>4Q 2020 annual review: no significant changes; references reviewed and updated.</td>
<td>08.11.20</td>
<td>11.20</td>
</tr>
<tr>
<td>RT2: added new subcutaneous dosage form Kesimpta to the policy for the treatment of multiple sclerosis; added primary progressive MS as a diagnosis not covered; added Commercial line of business to the policy.</td>
<td>10.06.20</td>
<td>02.21</td>
</tr>
</tbody>
</table>
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.